657 related articles for article (PubMed ID: 16564783)
21. Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy.
Mok CC; Lau CS; Wong RW
Arthritis Rheum; 1998 May; 41(5):831-7. PubMed ID: 9588734
[TBL] [Abstract][Full Text] [Related]
22. Longterm followup of childhood lupus nephritis.
Hagelberg S; Lee Y; Bargman J; Mah G; Schneider R; Laskin C; Eddy A; Gladman D; Urowitz M; Hebert D; Silverman E
J Rheumatol; 2002 Dec; 29(12):2635-42. PubMed ID: 12465165
[TBL] [Abstract][Full Text] [Related]
23. Treatment and renal outcome of lupus nephritis: single center experience.
Go KW; Teo SM
Med J Malaysia; 2006 Oct; 61(4):447-50. PubMed ID: 17243522
[TBL] [Abstract][Full Text] [Related]
24. Systemic lupus erythematosus in Thai children: clinicopathologic findings and outcome in 82 patients.
Pattaragarn A; Sumboonnanonda A; Parichatikanond P; Supavekin S; Suntornpoch V; Vongjirad A
J Med Assoc Thai; 2005 Nov; 88 Suppl 8():S232-41. PubMed ID: 16856445
[TBL] [Abstract][Full Text] [Related]
25. Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis.
Gunnarsson I; Sundelin B; Jónsdóttir T; Jacobson SH; Henriksson EW; van Vollenhoven RF
Arthritis Rheum; 2007 Apr; 56(4):1263-72. PubMed ID: 17393458
[TBL] [Abstract][Full Text] [Related]
26. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis.
De Groot K; Rasmussen N; Bacon PA; Tervaert JW; Feighery C; Gregorini G; Gross WL; Luqmani R; Jayne DR
Arthritis Rheum; 2005 Aug; 52(8):2461-9. PubMed ID: 16052573
[TBL] [Abstract][Full Text] [Related]
27. Treatment of Churg-Strauss syndrome without poor-prognosis factors: a multicenter, prospective, randomized, open-label study of seventy-two patients.
Ribi C; Cohen P; Pagnoux C; Mahr A; Arène JP; Lauque D; Puéchal X; Letellier P; Delaval P; Cordier JF; Guillevin L;
Arthritis Rheum; 2008 Feb; 58(2):586-94. PubMed ID: 18240234
[TBL] [Abstract][Full Text] [Related]
28. Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus.
Somers EC; Marder W; Christman GM; Ognenovski V; McCune WJ
Arthritis Rheum; 2005 Sep; 52(9):2761-7. PubMed ID: 16142702
[TBL] [Abstract][Full Text] [Related]
29. Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis.
Takada K; Arefayene M; Desta Z; Yarboro CH; Boumpas DT; Balow JE; Flockhart DA; Illei GG
Arthritis Rheum; 2004 Jul; 50(7):2202-10. PubMed ID: 15248218
[TBL] [Abstract][Full Text] [Related]
30. Clinical predictors of recovery and complications in the management of recent-onset renal failure in lupus nephritis: a Chinese experience.
Liang L; Yang X; Xu H; Zhan Z; Ye Y; Yu X; Chen W
J Rheumatol; 2004 Apr; 31(4):701-6. PubMed ID: 15088294
[TBL] [Abstract][Full Text] [Related]
31. A randomized pilot trial comparing cyclosporine and azathioprine for maintenance therapy in diffuse lupus nephritis over four years.
Moroni G; Doria A; Mosca M; Alberighi OD; Ferraccioli G; Todesco S; Manno C; Altieri P; Ferrara R; Greco S; Ponticelli C
Clin J Am Soc Nephrol; 2006 Sep; 1(5):925-32. PubMed ID: 17699309
[TBL] [Abstract][Full Text] [Related]
32. The long-term outcome of 93 patients with proliferative lupus nephritis.
Moroni G; Quaglini S; Gallelli B; Banfi G; Messa P; Ponticelli C
Nephrol Dial Transplant; 2007 Sep; 22(9):2531-9. PubMed ID: 17510096
[TBL] [Abstract][Full Text] [Related]
33. Prognostic factors in diffuse proliferative lupus nephritis.
Abraham MA; Korula A; Jayakrishnan K; John GT; Thomas PP; Jacob CK
J Assoc Physicians India; 1999 Sep; 47(9):862-5. PubMed ID: 10778652
[TBL] [Abstract][Full Text] [Related]
34. [Intermittent intravenous administration of cyclophosphamide in patients with lupus nephritis].
Morović-Vergles J; Galesić K; Dancuo I; Vergles D
Acta Med Croatica; 2004; 58(1):13-7. PubMed ID: 15125388
[TBL] [Abstract][Full Text] [Related]
35. [Cyclophosphamide induced amenorrhoea in pre-menopausal women with systemic lupus erythematosus].
Cunha I; Saavedra MJ; Pereira da Silva JA; Malcata A
Acta Reumatol Port; 2008; 33(1):69-76. PubMed ID: 18344924
[TBL] [Abstract][Full Text] [Related]
36. Anti-Ccl2 Spiegelmer permits 75% dose reduction of cyclophosphamide to control diffuse proliferative lupus nephritis and pneumonitis in MRL-Fas(lpr) mice.
Kulkarni O; Eulberg D; Selve N; Zöllner S; Allam R; Pawar RD; Pfeiffer S; Segerer S; Klussmann S; Anders HJ
J Pharmacol Exp Ther; 2009 Feb; 328(2):371-7. PubMed ID: 18997060
[TBL] [Abstract][Full Text] [Related]
37. Ovarian failure and flares of systemic lupus erythematosus.
Mok CC; Wong RW; Lau CS
Arthritis Rheum; 1999 Jun; 42(6):1274-80. PubMed ID: 10366122
[TBL] [Abstract][Full Text] [Related]
38. EULAR randomised controlled trial of pulse cyclophosphamide and methylprednisolone versus continuous cyclophosphamide and prednisolone followed by azathioprine and prednisolone in lupus nephritis.
Yee CS; Gordon C; Dostal C; Petera P; Dadoniene J; Griffiths B; Rozman B; Isenberg DA; Sturfelt G; Nived O; Turney JH; Venalis A; Adu D; Smolen JS; Emery P
Ann Rheum Dis; 2004 May; 63(5):525-9. PubMed ID: 15082482
[TBL] [Abstract][Full Text] [Related]
39. Synchronised therapy and high-dose cyclophosphamide in proliferative lupus nephritis.
Danieli MG; Palmieri C; Salvi A; Refe MC; Strusi AS; Danieli G
J Clin Apher; 2002; 17(2):72-7. PubMed ID: 12210709
[TBL] [Abstract][Full Text] [Related]
40. Effective treatment administration of cyclophosphamide in membranous nephropathy.
Dede F; Ayili D; Sahiner S
J Nephrol; 2008; 21(4):560-5. PubMed ID: 18651546
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
